MiniMed (MMED) reported a fiscal Q4 loss Wednesday of $0.68 per diluted share, unchanged from a year earlier.
Revenue for the quarter ended April 24 was $837 million, up from $724 million a year earlier.
Analysts polled by FactSet expected $827.9 million.
For fiscal 2027, the company expects organic revenue growth of approximately 10%.
MiniMed shares were up 5.7% in premarket activity.